795307-83-4

Basic information

• Product Name: Carbamic acid, [3-amino-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 795307-83-4
• Molecular Formula: C12H15F3N2O2
• Molecular Weight: 276.259
• Mol File: 795307-83-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [3-amino-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [3-amino-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester(795307-83-4)
• EPA Substance Registry System: Carbamic acid, [3-amino-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester(795307-83-4)

Safety Data

• Hazardous Substances Data: 795307-83-4(Hazardous Substances Data)

Upstream product

• 401-94-5 3-nitro-5-(trifluoromethyl)-phenylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 368-53-6 5-(trifluoromethyl)benzene-1,3-diamine 

Downstream Products

• 1365803-19-5 N-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)benzene-1,3-diamine hydrochloride 
• 1097619-67-4 C₁₆H₂₄F₃N₃O₂ 
• 845797-48-0 benzyl 3-(3-(tert-butoxycarbonyl)-5-(trifluoromethyl)phenylamino)-3-oxopropanoate 
• 847845-28-7 benzyl 3-(3-(tert-butoxycarbonyl)amino-5-(trifluoromethyl)phenylamino)-3-oxopropanoate 

Relevant articles and documents

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties

Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.

N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MCP-1 of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.